Radiopharm Theranostics (ASX:RAD) EBITDA Margin %: -816.45% (As of Jun. 2025)


What is Radiopharm Theranostics EBITDA Margin %?

Radiopharm Theranostics ASX:RAD -5.00% EBITDA Margin % is -816.45% as of Jun. 2025. The stock has 5 warning signs investors should review. Among 945 Biotechnology companies, Radiopharm Theranostics ranks worse than 79.89% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Radiopharm Theranostics's EBITDA for the six months ended in Jun. 2025 was A$-18.36 Mil. Radiopharm Theranostics's Revenue for the six months ended in Jun. 2025 was A$2.25 Mil. Therefore, Radiopharm Theranostics's EBITDA margin for the quarter that ended in Jun. 2025 was -816.45%.

Radiopharm Theranostics  (ASX:RAD) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Radiopharm Theranostics EBITDA Margin % Related Terms

Radiopharm Theranostics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Radiopharm Theranostics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Radiopharm Theranostics EBITDA Margin % Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
EBITDA Margin %
-199,588.89 -11,808.56 -15,786.62 -1,050.56

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
EBITDA Margin % Get a 7-Day Free Trial 0.00 0.00 -7,529.10 -1,431.00 -816.45

ASX:RAD vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Radiopharm Theranostics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Radiopharm Theranostics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Radiopharm Theranostics's EBITDA Margin % falls into.


Radiopharm Theranostics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Radiopharm Theranostics's EBITDA Margin % for the fiscal year that ended in Jun. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-38.167/3.633
=-1,050.56 %

Radiopharm Theranostics's EBITDA Margin % for the quarter that ended in Jun. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2025 )/Revenue (Q: Jun. 2025 )
=-18.362/2.249
=-816.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -816.45% mean?
Radiopharm Theranostics (ASX:RAD) has a EBITDA Margin % of -816.45% as of Jun. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Radiopharm Theranostics and its competitors. According to the industry distribution chart, Radiopharm Theranostics ranks #755 out of 945 companies in the Biotechnology industry, placing it in the top 79.9%.
Is Radiopharm Theranostics' EBITDA Margin % too high?
Radiopharm Theranostics' current EBITDA Margin % is -816.45%. Based on the distribution chart, Radiopharm Theranostics ranks #755 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Radiopharm Theranostics' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Radiopharm Theranostics ranks #755 out of 945 companies for EBITDA Margin %. This places Radiopharm Theranostics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Radiopharm Theranostics and its competitors. Radiopharm Theranostics's current EBITDA Margin % is -816.45%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Radiopharm Theranostics (ASX:RAD) has a current EBITDA Margin % of -816.45%. The current EBITDA Margin % is -816.45%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Radiopharm Theranostics (ASX:RAD), the current EBITDA Margin % is -816.45% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Radiopharm Theranostics Business Description

Other Exchanges RADX:USA
Address 62 Lygon Street, Suite 1, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.